Long-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study

Long-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study

Background and Objectives: Empagliflozin, a sodium glucose cotransporter-2 inhibitor, was recently evaluated in a randomized, controlled trial (RCT) in drug-naïve Type 2 diabetes mellitus (T2DM) patients managed on diet and exercise therapy. Efficacy and safety of empagliflozin in Indian subgroup of...

Full description

Bibliographic Details
Main Authors: Sunil Gupta, Shehla Shaikh, Pooja Joshi, Shraddha Bhure, Viraj Suvarna
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Drug naïve
empagliflozin
Indian subgroup
type 2 diabetes
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=2;spage=286;epage=292;aulast=Gupta

Internet

http://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=2;spage=286;epage=292;aulast=Gupta

Similar Items